FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288045177> ?p ?o ?g. }

• W4288045177 abstract "A combination of glucocorticoids with mycophenolate is recommended by current guidelines to boost response to Graves' orbitopathy (GO) therapy. This study was designed to evaluate the therapeutic effects and safety of methotrexate (MTX) plus reduced (3.0 g) or full-dose (4.5 g) i.v. methylprednisolone (MP) vs full-dose i.v. MP alone.This was a prospective, randomized, observer-masked, single-center clinical trial conducted in a tertiary clinical center. Ninety-seven patients with active moderate-to-severe GO were screened and 90 patients underwent randomization between April 2018 and Oct 2019. All patients completed 12 weeks of treatment and received clinical assessment. The patients received either MP 4.5 g only, MP 4.5 g plus oral MTX, or MP 3.0 g plus oral MTX. The primary outcome was the CAS response at week 12. Secondary outcomes were adverse events and other individual ophthalmic parameters.At week 12, 53.3% of MP, 76.7% of reduced MP plus MTX, and 76.7% of MP plus MTX achieved a CAS response, although the difference was not significant (P = 0.1). The overall response rates of the MP group, the reduced MP plus MTX group, and the MP plus MTX group were 43.3%, 53.3%, and 60%, respectively (P = 0.5). Subgroup analysis found that smoking status interacted with marginal significance with treatment effect (P = 0.048). Importantly, adverse event incidence was significantly lower in the reduced MP + MTX group (P = 0.017).Our study shows that reduced MP plus MTX therapy is effective and safer in treating active and moderate-to-severe GO patients than 4.5 g MP monotherapy." @default.
• W4288045177 created "2022-07-27" @default.
• W4288045177 creator A5000596937 @default.
• W4288045177 creator A5007123441 @default.
• W4288045177 creator A5011894823 @default.
• W4288045177 creator A5013665491 @default.
• W4288045177 creator A5017748489 @default.
• W4288045177 creator A5026085729 @default.
• W4288045177 creator A5034127226 @default.
• W4288045177 creator A5042476256 @default.
• W4288045177 date "2022-10-01" @default.
• W4288045177 modified "2023-10-14" @default.
• W4288045177 title "Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves’ orbitopathy" @default.
• W4288045177 cites W1479829890 @default.
• W4288045177 cites W1997419027 @default.
• W4288045177 cites W2010192466 @default.
• W4288045177 cites W2022755186 @default.
• W4288045177 cites W2023660047 @default.
• W4288045177 cites W2038106393 @default.
• W4288045177 cites W2048697130 @default.
• W4288045177 cites W2052463348 @default.
• W4288045177 cites W2071406318 @default.
• W4288045177 cites W2091815611 @default.
• W4288045177 cites W2110418038 @default.
• W4288045177 cites W2120143305 @default.
• W4288045177 cites W2122407290 @default.
• W4288045177 cites W2133472072 @default.
• W4288045177 cites W2136188216 @default.
• W4288045177 cites W2138922798 @default.
• W4288045177 cites W2151081127 @default.
• W4288045177 cites W2334870842 @default.
• W4288045177 cites W2611131029 @default.
• W4288045177 cites W2741570005 @default.
• W4288045177 cites W2748970558 @default.
• W4288045177 cites W2759425881 @default.
• W4288045177 cites W2786016821 @default.
• W4288045177 cites W2786397131 @default.
• W4288045177 cites W2792574976 @default.
• W4288045177 cites W2809133669 @default.
• W4288045177 cites W2885162095 @default.
• W4288045177 cites W2892405394 @default.
• W4288045177 cites W2914776081 @default.
• W4288045177 cites W2972552619 @default.
• W4288045177 cites W2979313800 @default.
• W4288045177 cites W3001519864 @default.
• W4288045177 cites W3003048801 @default.
• W4288045177 cites W3007527874 @default.
• W4288045177 cites W3048565585 @default.
• W4288045177 cites W3087881931 @default.
• W4288045177 cites W3153696862 @default.
• W4288045177 cites W3185041154 @default.
• W4288045177 cites W3186410608 @default.
• W4288045177 cites W4280598314 @default.
• W4288045177 doi "https://doi.org/10.1530/etj-22-0017" @default.
• W4288045177 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35900774" @default.
• W4288045177 hasPublicationYear "2022" @default.
• W4288045177 type Work @default.
• W4288045177 citedByCount "0" @default.
• W4288045177 crossrefType "journal-article" @default.
• W4288045177 hasAuthorship W4288045177A5000596937 @default.
• W4288045177 hasAuthorship W4288045177A5007123441 @default.
• W4288045177 hasAuthorship W4288045177A5011894823 @default.
• W4288045177 hasAuthorship W4288045177A5013665491 @default.
• W4288045177 hasAuthorship W4288045177A5017748489 @default.
• W4288045177 hasAuthorship W4288045177A5026085729 @default.
• W4288045177 hasAuthorship W4288045177A5034127226 @default.
• W4288045177 hasAuthorship W4288045177A5042476256 @default.
• W4288045177 hasBestOaLocation W42880451771 @default.
• W4288045177 hasConcept C126322002 @default.
• W4288045177 hasConcept C141071460 @default.
• W4288045177 hasConcept C197934379 @default.
• W4288045177 hasConcept C204243189 @default.
• W4288045177 hasConcept C2776804153 @default.
• W4288045177 hasConcept C2780073493 @default.
• W4288045177 hasConcept C2780372218 @default.
• W4288045177 hasConcept C2781059491 @default.
• W4288045177 hasConcept C535046627 @default.
• W4288045177 hasConcept C71924100 @default.
• W4288045177 hasConcept C90924648 @default.
• W4288045177 hasConceptScore W4288045177C126322002 @default.
• W4288045177 hasConceptScore W4288045177C141071460 @default.
• W4288045177 hasConceptScore W4288045177C197934379 @default.
• W4288045177 hasConceptScore W4288045177C204243189 @default.
• W4288045177 hasConceptScore W4288045177C2776804153 @default.
• W4288045177 hasConceptScore W4288045177C2780073493 @default.
• W4288045177 hasConceptScore W4288045177C2780372218 @default.
• W4288045177 hasConceptScore W4288045177C2781059491 @default.
• W4288045177 hasConceptScore W4288045177C535046627 @default.
• W4288045177 hasConceptScore W4288045177C71924100 @default.
• W4288045177 hasConceptScore W4288045177C90924648 @default.
• W4288045177 hasIssue "5" @default.
• W4288045177 hasLocation W42880451771 @default.
• W4288045177 hasLocation W42880451772 @default.
• W4288045177 hasLocation W42880451773 @default.
• W4288045177 hasOpenAccess W4288045177 @default.
• W4288045177 hasPrimaryLocation W42880451771 @default.
• W4288045177 hasRelatedWork W1964352248 @default.
• W4288045177 hasRelatedWork W2047967234 @default.
• W4288045177 hasRelatedWork W2062314770 @default.
• W4288045177 hasRelatedWork W2122058541 @default.

• next